Advertisement

Topics

Aryl S.A Company Profile

14:33 EST 18th December 2018 | BioPortfolio

ARYLS.A.started its business as a pharmachemical company in 1998.The manufacturing site and the administration offices are located in Bureros Aires,Aregentina.The Company employs more than 100 people

Location

Tucuman 141,4k
Buenos Aires
Buenos Aires
C1049AAC
Argentina

Contact

Phone: 5411 4315 0840
Email: aryl@aryl.com.ar


News Articles [9 Associated News Articles listed on BioPortfolio]

Catalytic activation of unstrained C(aryl)–C(aryl) bonds in 2,2′-biphenols

Narrow-band single-photon emission through selective aryl functionalization of zigzag carbon nanotubes

TGFβ1 signaling sustains aryl hydrocarbon receptor (AHR) expression and restrains the pathogenic potential of TH17 cells by an AHR-independent mechanism

Metathesis-active ligands enable a catalytic functional group metathesis between aroyl chlorides and aryl iodides

Ah, Just Pour It Into Salt Water

Today’s post is one for my fellow organic chemists to wonder over. This new paper from a group at the University of Bari describes a palladium-catalyzed coupling reaction of alkyllithiums and a...

GSK Sells Psoriasis/Dermatitis Candidate Tapinarof to Dermavant

GlaxoSmithKline (GSK) said today that it has sold mostly-global rights to its Phase III-bound psoriasis and atopic dermatitis candidate tapinarof (GSK2894512) to Dermavant Sciences for up to £250...

Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR Pipeline Review, H1 2018 [Report Updated: 12062018] Prices from USD $3500

Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR Pipeline Review, H1 2018SummaryAryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or ...

Dermavant to buy rights to tapinarof from GSK for £250m

GSK announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA...

Drugs and Medications [0 Results]

None

PubMed Articles [263 Associated PubMed Articles listed on BioPortfolio]

Synthesis of Aryl Trimethylstannane via BF3·OEt2-mediated Cross-Coupling of Hexaalkyl Distannane Reagent with Aryl Triazene at Room Temperature.

BF3·OEt2-mediated cross-coupling of (SnMe3)2 with aryl triazene offers a new strategy for the synthesis of aryl stannane. A variety of synthetically useful aryl trimethylstannanes were produced in mo...

Fullerene-Cation-Mediated Noble-Metal-Free Direct Introduction of Functionalized Aryl Groups onto 60Fullerene.

Aryl[60]fullerenyl cations (ArC), which were generated by heating aryl[60]fullerenyl dimers (ArC-CAr) to generate aryl[60]fullerenyl radicals (ArC) followed by oxidation using Cu(II) salts (Cu(BF)(aq)...

Pyrimidine as an Aryl C-H Activating Group.

The Pd-catalyzed regioselective C-H activation/arylation, /iodination, and/acetoxylation reactions of 4-arylpyrimidines using aryl iodides, N-iodosuccinimide, and (diacetoxyiodo)benzene respectively a...

N-Arylation of DABCO with Diaryliodonium Salts: General Synthesis of N-Aryl-DABCO Salts as Precursors for 1,4-Disubstituted Piperazines.

Employing DABCO as a substrate, aryl(mesityl)iodonium triflates are introduced as arylating agents for a tertiary sp-nitrogen. Mild conditions and exceptional selectivity of the aryl group transfer al...

Synthesis and dopaminergic activity of a series of new 1-aryl tetrahydroisoquinolines and 2-substituted 1-aryl-3-tetrahydrobenzazepines.

A series of new 1-aryl-6,7-dihydroxy tetrahydroisoquinolines with several substitution patterns in the 1-aryl group at C-1 were prepared in good yields. The influence of each substituent on the affini...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

The prognosis for patients with metastatic or locally advanced hepatocellular carcinoma (HCC) is poor. The role of conventional systemic chemotherapy has been very limited because most ch...

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

This study will investigate the effects and side effects of BAY 43-9006 in patients with advanced, recurrent, or refractory non-small cell lung cancer (NSCLC). BAY 43-9006 is one of a new ...

Companies [1 Associated Companies listed on BioPortfolio]

Aryl S.A

ARYLS.A.started its business as a pharmachemical company in 1998.The manufacturing site and the administration offices are located in Bureros Aires,Aregentina.The Company employs more than 100 people

More Information about "Aryl S.A" on BioPortfolio

We have published hundreds of Aryl S.A news stories on BioPortfolio along with dozens of Aryl S.A Clinical Trials and PubMed Articles about Aryl S.A for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aryl S.A Companies in our database. You can also find out about relevant Aryl S.A Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record